Combination treatment for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult with metastatic colorectal cancer that has not responded to previous treatments.
- You must be expected to live at least 12 weeks.
- You have not had a prior treatment targeting the c-Met protein or certain topoisomerase inhibitors.
- You have no known allergies to the study drugs or related compounds.
- You do not have a history of significant drug or alcohol abuse in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a combination of three drugs—tucidinostat, sintilimab, and bevacizumab—for people with a specific type of advanced colorectal cancer (MSS or pMMR) that has gotten worse after standard treatments. The goal is to see if this new mix can help shrink or slow the tumor.
This trial tests a new drug (TQB2930) combined with chemotherapy, with or without another drug called bevacizumab, for people whose colorectal cancer has spread or cannot be removed by surgery and has a specific protein called HER2. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
This trial tests two different drug combinations for people with advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if one combination works as well as the other, potentially offering a new option.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.